These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32382078)

  • 1. Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL.
    Tutrone R; Donovan MJ; Torkler P; Tadigotla V; McLain T; Noerholm M; Skog J; McKiernan J
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):607-614. PubMed ID: 32382078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
    Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis.
    Tutrone R; Lowentritt B; Neuman B; Donovan MJ; Hallmark E; Cole TJ; Yao Y; Biesecker C; Kumar S; Verma V; Sant GR; Alter J; Skog J
    Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):596-601. PubMed ID: 37193776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies.
    Margolis E; Brown G; Partin A; Carter B; McKiernan J; Tutrone R; Torkler P; Fischer C; Tadigotla V; Noerholm M; Donovan MJ; Skog J
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):296-301. PubMed ID: 34593984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care.
    Moul JW; Sant GR
    Can J Urol; 2022 Aug; 29(4):11224-11230. PubMed ID: 35969726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
    McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
    JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.
    McKiernan J; Noerholm M; Tadigotla V; Kumar S; Torkler P; Sant G; Alter J; Donovan MJ; Skog J
    BMC Urol; 2020 Sep; 20(1):138. PubMed ID: 32873277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome.
    Kretschmer A; Tutrone R; Alter J; Berg E; Fischer C; Kumar S; Torkler P; Tadigotla V; Donovan M; Sant G; Skog J; Noerholm M
    World J Urol; 2022 Apr; 40(4):983-989. PubMed ID: 35084544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
    Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
    Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of noninvasive biomarker testing and MRI to predict a prostate cancer diagnosis.
    Sultan MI; Huynh LM; Kamil S; Abdelaziz A; Hammad MA; Gin GE; Lee DI; Youssef RF
    Int Urol Nephrol; 2024 Feb; 56(2):539-546. PubMed ID: 37742327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a CE-IVD, urine exosomal RNA expression assay for risk assessment of prostate cancer prior to biopsy.
    Kretschmer A; Kajau H; Margolis E; Tutrone R; Grimm T; Trottmann M; Stief C; Stoll G; Fischer CA; Flinspach C; Albrecht A; Meyer L; Priewasser T; Enderle D; Müller R; Torkler P; Alter J; Skog J; Noerholm M
    Sci Rep; 2022 Mar; 12(1):4777. PubMed ID: 35314720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
    Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
    Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of multiple secondary combined tests in prostate cancer screening.
    Dudinec JV; Wang SM; Kotamarti S; Morris KE; Polascik TJ; Moul JW
    Can J Urol; 2023 Jun; 30(3):11538-11544. PubMed ID: 37344464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving prostate cancer detection in veterans through the development of a clinical decision rule for prostate biopsy.
    Hill OT; Mason TJ; Schwartz SW; Foulis PR
    BMC Urol; 2013 Jan; 13():6. PubMed ID: 23356551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
    Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
    Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
    Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
    Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.